MODEL‐AD Pre‐Clinical Testing Core: A Precision Medicine Pipeline for Preclinical Testing of Alzheimer’s Disease Therapeutic Candidates
Paul R Territo · 2025
Read MODEL‐AD Pre‐Clinical Testing Core: A Precision Medicine Pipeline for Preclinical Testing of Alzheimer’s Disease Therapeutic Candidates by Paul R Territo (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11709537.txt.
Description
Paul Territo describes a testing pipeline built to screen Alzheimer's drug candidates in mice more honestly, in a 2025 paper. Hundreds of drugs have eased memory loss in animal studies over the past thirty years, yet none has worked in human trials for this disease. The pipeline, part of the MODEL-AD program, was designed to catch weak candidates early with strict go or no-go checks.
Each drug is matched to the mouse model that best fits how the drug acts. A first screen checks the drug's identity, stability, and whether enough of it reaches the brain. Passing drugs move to target checks with brain scans, then to behavior tests and gene and protein studies. Trial runs with known drugs showed why strict quality checks matter at each step.
Catalog record
| CREATOR | Paul R Territo |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |